Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
Key Highlights
- ➤Savings Plan cuts annualized operating costs approximately $9.3 million
- ➤Mesa will reinvest approximately $4.3 million, leaving $5.0 million net savings
- ➤Restructuring eliminates approximately 40 positions, or 6% of employees
- ➤Clinical Genomics revenue will decline, but profitability and gross margin should improve
- ➤Restructuring charges estimated at $2.6 million-$3.4 million, mostly in fiscal 2027
Expert Statements
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“Mesa is a set of durable, regulation-embedded franchises with real and growing earnings power, and fixable execution problems we have already begun to fix”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“My focus is disciplined execution and consistent, profitable growth across our four divisions.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“As I said on our first quarter call, we are managing Clinical Genomics deliberately, with full attention to its cost structure and returns.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“Following the business reviews I have completed over my first six months, we are managing it for profitability, not for scale.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“This is not a broad cost reduction.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“We are focusing Clinical Genomics on pharmacogenomics and oncology, on customer accounts that use the instrument at scale, and we are sizing the organization for that.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“Revenue will be lower as a result, but we expect profitability to be meaningfully higher as the cost comes out, and gross profit percentage to improve, because the revenue we are stepping away from is the lowest-margin revenue we have in Clinical Genomics.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“We are also redirecting resources to accelerate standard product launches, the fastest-growing part of the Clinical Genomics portfolio.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“Our obligation is to make every business in this portfolio earn its cost of capital, and we will report against that standard.”
LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million. The Savings Plan consists of a global restructuring program (the "Restructuring Program"), a reduction in our San Diego, California facility footprint and reduced third-party spending. We plan to reinvest approximately $4.3 million of the savings into the business to drive profitable growth, for a net annualized cost reduction of approximately $5.0 million.
The Restructuring Program is designed to allocate resources toward opportunities that we expect to expand future profitability and create long-term value for our shareholders. As part of the Restructuring Program, we will eliminate approximately 40 positions, or approximately 6% of Mesa’s total employee base, with limited impact on manufacturing operations.
Get started
Create a free account to read the full story.